Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Standard Risk B-precursor Acute Lymphoblastic Leukemia

Next Previous
X
Search
Trial Profile

Standard Risk B-precursor Acute Lymphoblastic Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Pegaspargase (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Doxorubicin; Doxorubicin; Mercaptopurine; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jun 2021 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Results assessing clinical, and outcome data for Down syndrome and non-Down syndrome from AALL0331, AALL0932, AALL0232 and AALL1131, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Apr 2020 Results from AALL0331(n=5195) and AALL0232 (n=3001) assessing Impact of Asparaginase Discontinuation and Erwinia as a substitution on Outcome in Childhood Acute Lymphoblastic Leukemia, published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top